Lorlatinib
博瑞纳(Lorbrena)
A third-generation ALK targeted pill for resistant disease and brain metastases.
At a glance
China price
Verified pricing is not currently available.
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
Source(s)
- https://www.himd.com/lorlatinib/22237888
Secondary source (media / community / commercial)
NRDL (national insurance)
In NRDL.
Regulatory status
NMPA approved; NRDL 202312
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
ALK-positive NSCLC, first-line or after earlier ALK drugs.
202312
Sources & verification
- https://www.himd.com/lorlatinib/22237888 — Secondary source (media / community / commercial)
Reader discussion
Public comments about Lorlatinib. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.